-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Eledon Pharmaceuticals, Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q2 2014 to Q3 2024.
- Eledon Pharmaceuticals, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending September 30, 2024 was $77.1M.
- Eledon Pharmaceuticals, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2016 was -$37.9M, a 16% increase from 2015.
- Eledon Pharmaceuticals, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2015 was -$45.1M, a 93.8% decline from 2014.
- Eledon Pharmaceuticals, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2014 was -$23.3M, a 48.1% decline from 2013.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)